Doctor Daniel Peter Andersson
Karolinska Institute, Stockholm (Sweden)
Association between treatment with phosphodiesterase-5 inhibitors, versus alprostadil and survival in patients with coronary artery disease
Event: ESC Congress 2018
Topic: Cardiovascular Risk Assessment, Other
Session: Secondary prevention
ESC 365 is supported by
